AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11581449
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 10 to 20 ppm (high-dose group)
Trial: 11581449
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of iNO after initial treatment
Trial: 10923477
Drug: H2 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 strain vaccine (10^7.0 TCID50)
Trial: 10923477
Drug: LA-1 strain
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-1 strain vaccine (10^6.75 TCID50)
Trial: 10923477
Drug: Combined efficacy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined efficacy of H2 and LA-1 vaccines
Trial: 29791895
Drug: Postprandial ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial ingestion of esomeprazole 40 mg
Trial: 29791895
Drug: Preprandial ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial ingestion of esomeprazole 40 mg
Trial: 25636696
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg once daily for 5 days + HCTZ 25 mg once daily for 4 days
Trial: 25636696
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg once daily for 5 days + TOR 5 mg once daily for 4 days
Trial: 25636696
Drug: HCTZ 25
RxNorm normalized name: HCTZ 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg once daily
Trial: 25636696
Drug: TOR 5
RxNorm normalized name: T-Connector 5"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOR 5 mg once daily
Trial: 23916935
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) niacin 1,500 to 2,000 mg
Trial: 23916935
Drug: Minimal immediate-release
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal immediate-release niacin (≤ 150 mg) as placebo
Trial: 18945506
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS (2x10(10) CFU of each strain daily)
Trial: 10506617
Drug: CT +
RxNorm normalized name: Aveeno Protect + Hydrate SPF70 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT + RT (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 every 21 days for up to four cycles followed by radical radiotherapy)
Trial: 10506617
Drug: CT +
RxNorm normalized name: Aveeno Protect + Hydrate SPF70 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT + PC (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 plus palliative care)
Trial: 10506617
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (RT or PC)
Trial: 26164621
Drug: Group family‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group family‐based cognitive behavioural therapy (CBT)
Trial: 19343318
Drug: Caroverine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroverine (80 mg)
Trial: 11057406
Drug: Intraderma injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderma injection of Tc‐99m nanocolloid
Trial: 11057406
Drug: Peritumoural injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoural injection of Tc‐99m nanocolloid
Trial: 11057406
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both injection methods
Trial: 8790025
Drug: Hirudin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (0.1 mg/kg bolus followed by infusion of 0.1 mg/kg per hour)
Trial: 8790025
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 U bolus followed by infusion of 1000 U/h)
Trial: 1535215
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin
Trial: 19923168
Drug: Ticagrelor (180‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180‐mg load, 90‐mg BID maintenance dose)
Trial: 19923168
Drug: Clopidogrel (600‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600‐mg load, 75‐mg/d maintenance dose)
Trial: 17876889
Drug: Low-dose intermittent
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intermittent interferon (IFN) therapy (3 MIU of natural IFN‐alpha intramuscularly 3 times weekly for at least 48 weeks)
Trial: 17876889
Drug: Low-dose intermittent
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intermittent interferon (IFN) therapy
Trial: 16009829
Drug: Latanoprost therapy
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost therapy alone
Trial: 16009829
Drug: Latanoprost-timolol-fixed combination
RxNorm normalized name: latanoprost / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost-timolol-fixed combination therapy
Trial: 12774194
Drug: Calcitriol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5 micro g p.o. b.i.d. for 14 days)
Trial: 8966497
Drug: Premarin 0.625
RxNorm normalized name: Premarin 0.625mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 0.625 mg
Trial: 8966497
Drug: Menorest 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest 50 mikrog/day and Premarin 0.625 mg
Trial: 1563807
Drug: Albendazole 10
RxNorm normalized name: albendazole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 10 mg/kg/day for four courses of 30 days with 15‐day drug‐free intervals
Trial: 1563807
Drug: Mebendazole 50‐70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 50‐70 mg/kg/day continuously for between 6 and 24 months
Trial: 6386490
Drug: UK‐38,485 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK‐38,485 50 mg
Trial: 16905139
Drug: High-dose lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lovastatin
Trial: 16905139
Drug: Low-dose lovastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lovastatin
Trial: 16905139
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effects (lovastatin and warfarin vs placebo)
Trial: 17315548
Drug: Transdermal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapeutic fentanyl (TTS‐F) patches releasing 25 microg fentanyl per hour
Trial: 17315548
Drug: Codeine/paracetamol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine/paracetamol (120 mg per day)
Trial: 12354129
Drug: Individualized recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized recombinant GH substitution (0.17 mg GH/day, titrated every 6-8 weeks)
Trial: 12354129
Drug: Individualized recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized recombinant GH substitution (0.17 mg GH/day, titrated to T(max) and then reduced to T(end))
Trial: 2299950
Drug: Blunt dissection
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blunt dissection tonsillectomy using suture ligatures for hemostasis, without postoperative antibiotics
Trial: 6109150
Drug: Dipyridamole (DPY),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (DPY), 100 mg a day and Aspirin (ASA), 1200 mg a day
Trial: 6109150
Drug: Dipyridamole (DPY)
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole (DPY) and Aspirin (ASA)
Trial: 23475825
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (IR-methylphenidate)
Trial: 23036139
Drug: Naturopathic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic and nutritional supplements (NNS)
Trial: 23036139
Drug: No Naturopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Naturopathic and nutritional supplements (NNS)
Trial: 19173973
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lamivudine and traditional Chinese medicine
Trial: 14594786
Drug: Spread A
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spread A (25 g/d containing 43 mg alpha‐TE and 0.45 mg carotenoids)
Trial: 14594786
Drug: Spread B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread B (25 g/d containing 111 mg alpha‐TE and 1.24 mg carotenoids)
Trial: 14594786
Drug: Spread C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread C (25 g/d containing 1.3 mg RRR‐alpha‐tocopherol without carotenoids)
Trial: 8853832
Drug: Granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2 mg oral dose
Trial: 1633756
Drug: Sham transdermal
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham transdermal stimulation
Trial: 6392119
Drug: xipamid (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xipamid (40 mg)
Trial: 6392119
Drug: hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (50 mg)
Trial: 6392119
Drug: xipamid (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xipamid (80 mg)
Trial: 6392119
Drug: hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (100 mg)
Trial: 29764262
Drug: IgPro20 (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgPro20 (20% IgG stabilized with L‐Proline)
Trial: 29764262
Drug: Subcutaneous method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous method
Trial: 26901268
Drug: Comparison treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison treatment with a print manual plus telephone follow‐ups
Trial: 15480323
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 2 years
Trial: 18508833
Drug: Consecutive C-reactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consecutive C-reactive protein (CRP) measurements on admission, day 3, and day 7 during follow-up of antibiotic treatment.
Trial: 15889132
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) therapy for 1 to 72 hours
Trial: 9202910
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg intravenous (i.v.)
Trial: 7960608
Drug: E (epirubicin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E (epirubicin) alone (90 mg/m2 day 1)
Trial: 7960608
Drug: 5‐FU (5-Fluorouracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (5-Fluorouracil) alone (500 mg/m2 days 1‐5)
Trial: 7960608
Drug: 5‐FU (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (400 mg/m2 days 1‐5) plus E (epirubicin) (90 mg/m2 day 1)
Trial: 30334066
Drug: Weekly cone
RxNorm normalized name: Pinus strobus cone extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cone beam CTs (CBCT)
Trial: 23884915
Drug: Oral T4
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral T4 (2 μg·kg⁻¹)
Trial: 23884915
Drug: Intravenous T4
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous T4 (2 μg·kg⁻¹)
Trial: 23884915
Drug: Oral T4
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral T4
Trial: 23884915
Drug: Intravenous T4
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous T4
Trial: 22043670
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (Fluoxetine Hydrochloride capsule, 20 mg, once a day)
Trial: 15304961
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of potassium iodide (38 mg of iodide)
Trial: 15304961
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of potassium iodide (76 mg of iodide)
Trial: 9299652
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (400 micrograms, 4 times daily for 3 days)
Trial: 31819393
Drug: Oscillatory PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oscillatory PEP (OPEP) therapy
Trial: 24005444
Drug: PEP therapy
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEP therapy
Trial: 31819393
Drug: PEP ±
RxNorm normalized name: Postexposure prophylaxis (PEP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP ± OM therapy
Trial: 22878749
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 1000 mg daily
Trial: 22878749
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 1000 mg daily plus erlotinib 150 mg
Trial: 20972904
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (group B)
Trial: 17097647
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) alone (100 mg/day from day 3 to day 7; n = 56)
Trial: 17097647
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) in combination with pure FSH (75 IU on day 3 and day 8; n = 54)
Trial: 17097647
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (parous women, n = 18)
Trial: 2407957
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (75 mg per day)
Trial: 394752
Drug: beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone dipropionate 800 microgram daily
Trial: 394752
Drug: beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone dipropionate 400 microgram daily
Trial: 25260444
Drug: Standard inguinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inguinal varicocelectomy plus oral L-carnitine therapy (250 mg 3 times a day for 6 months)
Trial: 22552034
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone supplementation (80 mg daily for 6 weeks)
Trial: 19959293
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment (IV opioids)
Trial: 18166126
Drug: Nystatin (nonabsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin (nonabsorbed antifungal drug)
Trial: 26028965
Drug: Anagrelide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide therapy
Trial: 12045085
Drug: Intramuscular droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular droperidol 2.5 mg
Trial: 12045085
Drug: Intramuscular dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular dimenhydrinate 50 mg
Trial: 9524997
Drug: 0.75% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% metronidazole vaginal gel (twice daily for 7 days)
Trial: 9524997
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (250 mg, three times daily for 7 days)
Trial: 9524997
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole and 0.75% metronidazole vaginal gel
Trial: 8585295
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate adsorbed vaccine
Trial: 8585295
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide adsorbed vaccine
Trial: 8305355
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg t.d.s.
Trial: 2533896
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg t.d.s.
Trial: 773484
Drug: Intraperitoneal noxytiolin
RxNorm normalized name: Noxytiolin
DrugBank: Noxytiolin (DB13838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal noxytiolin (Noxiflex) solution
Trial: 30949182
Drug: Extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis (ECP) therapy
Trial: 27119829
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day co-administered with atorvastatin 20 mg
Trial: 26030325
Drug: Doubling atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling atorvastatin dose
Trial: 24508320
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus treatment as usual
Trial: 22395889
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of ocular hypotensive medication
Trial: 17343552
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at low, medium, and high doses
Trial: 10578595
Drug: Composite Indian
RxNorm normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Indian herbal preparation (CIHP)
Trial: 8694025
Drug: Lactose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose supplementation (0.6 to 1.0 g.kg‐1.d‐1, divided into three doses) for 10 days
Trial: 8694025
Drug: Lactose challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose challenge (0.35 g/kg) after overnight fast
Trial: 6318345
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg per day ketoprofen alone
Trial: 6318345
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg per day ketoprofen combined with 1,500 mg aspirin
Trial: 26384629
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (listening to a recorded CD of music and songs preferred by the child)
Trial: 23790566
Drug: D-amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (0, 5, 10, and 20 mg)
Trial: 21283923
Drug: Both LF
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both LF and HF treatments
Trial: 19135671
Drug: Glimepiride (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (4 mg od)
Trial: 19135671
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg od)
Trial: 15380894
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg plain release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Trial: 15380894
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg slow release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Trial: 8062609
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg/day) for 48 months in normotensive patients (NE group)
Trial: 8062609
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg/day) for 48 months in well-controlled hypertensive patients (HE group)
Trial: 8062609
Drug: No enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No enalapril treatment in normotensive patients (NC group)
Trial: 8062609
Drug: No enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No enalapril treatment in well-controlled hypertensive patients (HC group)